Filing Flows › ANI Pharmaceuticals (ANIP) › Free cash flow
ANI Pharmaceuticals (ANIP) free cash flow by quarter
ANI Pharmaceuticals' free cash flow was $70.3M in Q3 2026 (third quarter 2026), +31% from Q2 2026. Over the last 7 quarters it ranged from $29.1M (Q4 2025) to $71.8M (Q2 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $70.3M | +31% | +85% |
| Q2 2026 | $53.6M | +3% | -25% |
| Q1 2026 | $52.3M | +80% | +61% |
| Q4 2025 | $29.1M | -23% | — |
| Q3 2025 | $38.0M | -47% | — |
| Q2 2025 | $71.8M | +121% | — |
| Q1 2025 | $32.5M | — | — |
Q3 2026 at a glance
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ANI Pharmaceuticals' free cash flow?
ANI Pharmaceuticals' free cash flow was $70.3M in Q3 2026 (third quarter 2026), +31% from Q2 2026.
How has ANI Pharmaceuticals' free cash flow changed?
Over the last 7 quarters it ranged from $29.1M (Q4 2025) to $71.8M (Q2 2025).